Proteochemometric modeling of the susceptibility of mutated variants of the HIV-1 virus to reverse transcriptase inhibitors

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Junaid, Muhammad ^a   Lapins, Maris ^a   Eklund, Martin ^a   Spjuth, Ola ^a   Wikberg, Jarl E S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; DIDANOSINE; DNA POLYMERASE; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHEMOMETRIC ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; PROTEOMICS; VIRUS GENOME; VIRUS ISOLATION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE; ANTIVIRAL RESISTANCE; BIOLOGICAL MODEL; DRUG DESIGN; DRUG SCREENING; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; PROTEIN TERTIARY STRUCTURE; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; MUTATION; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 78650736464     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014353     Document Type: Article

References (41)

1. Jingshan R, Stammers DK (2005) HIV Reverse Transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance. Trends Pharmacol Sci 26: 4-7.
2. UNAIDS and WHO: AIDS epidemic update 2009. Available: http://data. unaids.org/pub/Report/2009/2009_epidemic_update_en.pdf. Accessed 2010 Apr 26.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents inHIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009. Available: http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2010 Apr 26.
4. Parniak MA, Sluis-Cremer N (2000) Inhibitors of HIV-1 Reverse Transcriptase. Adv Pharmacol 49: 67-109.
5. Goff SP (1990) Retroviral Reverse Transcriptase: synthesis, structure, and function. J Acquir Immune Defic Syndr 3: 817-831.
6. De Clercq E (2002) Strategies in the design of anti-viral drugs. Nat Rev Drug Disc 1: 13-25.
7. Goody RS, Muller B, Restle T (1991) Factors contributing to the inhibition of HIV Reverse Transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Lett 7: 1-5.
8. Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483-489.
9. Gao F, Chen Y, Levy DN, Conway JA, Kepler TB, et al. (2004) Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious. J Virol 78: 2426-2433.
10. Beerenwinkel N, Daumer M, Oette M, Korn K, Hoffmann D, et al. (2003) Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 31: 3850-3855.
11. Beerenwinkel N, Sing T, Lengauer T, Rahnenfuhrer J Roomp K, et al. (2005) Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 21: 3943-3950.
12. Rhee SY, Taylor J, Wadhera G, Ben-Hur A, Brutlag DL, et al. (2006) Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci U S A 103: 17355-17360.
13. Kjaer J, Hoj L, Fox Z, Lundgren JD (2008) Prediction of phenotypic susceptibility to antiretroviral drugs using physicochemical properties of primary enzymatic structure combined with artificial neural networks. HIV Med 9: 642-652.
14. Saigo H, Uno T, Tsuda K (2007) Mining complex genotypic features for predicting HIV-1 drug resistance. Bioinformatics 23: 2455-2462.
15. Rosen-Zvi M, Altmann A, Prosperi M, Aharoni E, Neuvirth H, et al. (2008) Selecting anti-HIV therapies based on a variety of genomic and clinical factors. Bioinformatics 24: i399-406.
16. Altmann A, Däumer M, Beerenwinkel N, Peres Y, Schülter E, et al. (2009) Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. J Infect Dis 199: 999-1006.
17. Wikberg JE, Lapinsh M, Prusis P (2004) Proteochemometrics: A tool for modeling the molecular interaction space. In: Kubinyi H, Müller G, eds. Chemogenomics in Drug Discovery - A Medicinal Chemistry Perspective. Weinheim: Wiley-VCH. pp 289-309.
18. Lapinsh M, Prusis A, Gutcaits A, Lundstedt T, Wikberg JE (2001) Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. Biochim Biophys Acta 1525: 180-190.
19. Lapinsh M, Prusis P, Wikberg JE (2002) Proteochemometrics modeling of the interaction of amine G-protein coupled receptors with a diverse set of ligands. Mol Pharmacol 61: 1465-1475.
20. Lapinsh M, Prusis P, Mutule I, Mutulis I, Wikberg JE (2003) QSAR and proteochemometric analysis of the interaction of a series of organic compounds with melanocortin receptor subtypes. J Med Chem 46: 2572-2579.
21. Lapinsh M, Prusis P, Uhlén S, Wikberg JE (2005) Improved approach for proteochemometrics modeling: application to organic compound - amine G protein-coupled receptor interactions. Bioinformatics 21: 4289-4296.
22. Lapinsh M, Veiksina S, Uhlén S, Petrovska R, Mutule I, et al. (2005) Proteochemometric mapping of the interaction of organic compounds with melanocortin receptor subtypes. Mol Pharmacol 67: 50-59.
23. Prusis P, Muceniece R, Andersson P, Post C, Lundstedt T, et al. (2001) PLS modeling of chimeric MS04/MSH-peptide and MC1/MC3-receptor interactions reveals a novel method for the analysis of ligand-receptor interactions. Biochim Biophys Acta 1544: 350-357.
24. Strombergsson H, Prusis P, Midelfart H, Lapinsh M, Wikberg JE, et al. (2006) Rough set-based proteochemometrics modeling of G-protein-coupled receptorligand interactions. Proteins 63: 24-34.
25. Mandrika I, Prusis P, Yahorava S, Shikhagaie M, Wikberg JE (2007) Proteochemometric modeling of antibody-antigen interactions using SPOT synthesised peptide arrays. Protein Eng Des Sel 20: 301-307.
26. Kontijevskis A, Prusis P, Petrovska R, Yahorava S, Mutulis F, et al. (2007) A look inside HIV resistance through retroviral protease interaction maps. PLoS Comput Biol, Available: http://www.ploscompbiol.org/article/info%3Adoi% 2F10.1371%2Fjournal.pcbi.0030048 Accessed 2010 Apr 26 3.
27. Lapins M, Eklund M, Spjuth O, Prusis P, Wikberg JE (2008) Proteochemometric modeling of HIV protease susceptibility. BMC Bioinformatics 9. Available: http://www.biomedcentral.com/1471-2105/9/181 Accessed 2010 Apr 26 9.
28. Eriksson L, Johansson E (1996) Multivariate design and modeling in QSAR. Chemom Intell Lab 34: 1-19.
29. Wold S, Sjöström M, Eriksson L (2001) PLS-regression: a basic tool of chemometrics. Chemom Intell Lab 58: 109-130.
30. Wang K, Samudrala R, Mittler JE (2004) Antivirogram or phenosense: a comparison of their reproducibility and an analysis of their correlation. Antivir Ther 9: 703-712.
31. Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, et al. (2005) Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 10: 791-802.
32. Wagener J, Spjuth O, Willighagen EL, Wikberg JE (2009) XMPP for cloud computing in bioinformatics supporting discovery and invocation of asynchronous Web services. BMC Bioinformatics, Available: http://www.biomedcentral. com/1471-2105/10/279 Accessed 2010 Apr 26 10.
33. HIV Drug Research Center. Available: http://www.hivdrc.org Accessed 2010 Apr 26.
34. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, et al. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31: 298-303.
35. Release Notes for HIVdb, HIVseq, HIValg. Available: http://hivdb.stanford. edu/pages/asi/releaseNotes Accessed 1010 Jun 12.
36. Sandberg M, Eriksson L, Jonsson J, Sjöström M, Wold S (1998) New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. J Med Chem 41: 2481-2491.
37. Wold S, Esbensen K, Geladi P (1987) Principal component analysis. Chemom Intell Lab 2: 37-52.
38. Todeschini R, Consonni V (2000) Handbook of Molecular Descriptors. Weinheim: Wiley-VCH. 688 p.
39. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S (2001) Multi- and Megavariate Data Analysis. Principles and Applications. Umeå: Umetrics Academy. 533 p.
40. Trygg J, Wold S (2002) Orthogonal projections to partial least-squares (O-PLS). J Chemometr 16: 119-28.
41. Golbraikh A, Tropsha A (2002) Beware of q2! J Mol Graph Model 20: 269-276.